Transplantation

Drug Prevents Rejection in Kidney Transplant Patients

Published in Gene Therapy Weekly, February 2nd, 1998

A study published in The New England Journal of Medicine shows that Zenapax (Daclizumab), prevents rejection in kidney transplant patients.

Zenapax is a genetically engineered drug used in combination with other anti-rejection medications, significantly reduces the risk of acute rejection episodes in patients who undergo kidney transplants. Because Zenapax is a humanized monoclonal antibody, the body is less likely to recognize it as foreign.

Thus, its efficacy is less likely to be limited by the body's natural response to non-human antibodies. The study found that Zenapax reduces the incidence of kidney rejection episodes to as low as 22 percent,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-02-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry